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INTRODUCTION 
 
Articular cartilage from patients with osteoarthritis 
(OA) shows accumulation of dedifferentiated and 
senescent cells [1–4] together with increased 
inflammation and breakdown of cartilage extracellular 
matrix (ECM) [5]. Importantly, cartilage and synovial 
tissue from OA patients contain high levels of the gap 
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Articular cartilage and synovial tissue from patients with osteoarthritis (OA) show an overactivity of connexin43 
(Cx43) and accumulation of senescent cells associated with disrupted tissue regeneration and disease 
progression. The aim of this study was to determine the effect of oleuropein on Cx43 and cellular senescence 
for tissue engineering and regenerative medicine strategies for OA treatment. Oleuropein regulates Cx43 
promoter activity and enhances the propensity of hMSCs to differentiate into chondrocytes and bone cells, 
reducing adipogenesis. This small molecule reduce Cx43 levels and decrease Twist-1 activity in osteoarthritic 
chondrocytes (OACs), leading to redifferentiation, restoring the synthesis of cartilage ECM components (Col2A1 
and proteoglycans), and reducing the inflammatory and catabolic factors mediated by NF-kB (IL-1ß, IL-6, COX-2 
and MMP-3), in addition to lowering cellular senescence in OACs, synovial and bone cells. Our in vitro results 
demonstrate the use of olive-derived polyphenols, such as oleuropein, as potentially effective therapeutic 
agents to improve chondrogenesis of hMSCs, to induce chondrocyte re-differentiation in OACs and clearing out 
senescent cells in joint tissues in order to prevent or stop the progression of the disease. 
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junction protein connexin43 (Cx43). Targeting Cx43 
might be a promising approach to treat several age-
related and chronic degenerative diseases by modulating 
tissue regeneration, inflammation and response to injury 
[6]. Cx43 belongs to the integral membrane protein 
family called connexins, that enable direct 
communication between neighboring cells via 
hemichannels, gap junctions, extracellular vesicles and 
tunneling nanotubes [7]. Additionally, connexins act as 
signaling hubs regulating different signaling pathways 
via their cytoplasmic domains [2, 8]. Cx43 is the major 
Cx protein expressed in chondrocytes, synovial cells 
(SC) and bone cells (BC) [9–11] and it has been 
involved in normal development and function of joint 
tissues [12, 13] and joint disorders [9–11, 14, 15]  
 
During tissue regeneration and following injury, 
dedifferentiation, redifferentiation and senescence 
processes play finely tuned temporal and spatial roles to 
reverse the loss [2, 16]. In addition, accumulation of 
senescent cells is described to play a major role in OA 
progression [1, 17–22]. Cellular senescence is a stable 
cell-cycle arrest with increased expression of cell cycle 
inhibitors such as p16INK4A and enhanced synthesis of 
the senescence-associated secretory phenotype (SASP) 
factors, which mainly consist of inflammatory cytokines 
and ECM degrading enzymes, among other factors [23]. 
The elimination of senescent cells using senolytics has 
been described to attenuate cartilage and joint 
degeneration in OA [1, 24–26]. In fact, some of these 
drugs including UBX0101 and the natural-occurring 
flavone Fisetin [27, 28] with potential senolytic activity 
are currently under clinical trial for OA treatment 
(NCT04210986; NCT04349956; NCT04229225; 
NCT04129944) [29–32]. 
 
Cx43 has been involved in different phases of tissue 
regeneration including chronic inflammation, cell 
differentiation and cellular senescence [33, 34]. 
Overexpression of Cx43 and enhanced gap junction 
intercellular communication (GJIC) in osteoarthritic 
chondrocytes (OACs) compromise their ability to re-
differentiate, promoting a stem-like state by activating 
Twist-1, which leads to dedifferentiation via epithelial-
to-mesenchymal transition (EMT) [2]. However, we 
have also previously observed that high levels of Cx43 
lead to p53/p21-mediated cellular senescence [2]. 
Increased levels of Cx43 in OA cartilage is extensively 
described in the literature [9, 11, 35–37], as well as the 
presence of dedifferentiation (stem-like state) and 
proliferative chondrocytes [4, 38–44] together with the 
accumulation of senescent cells [1, 18, 20, 29], 
indicating that both phenotypes, dedifferentiated and 
senescent chondrocytes, co-exist in cartilage from OA 
patients and contribute to the progression of the disease. 
However, we have recently demonstrated that 
downregulation of Cx43 reduces stemness and 
accumulation of senescent cells, indicating that Cx43 
acts as a molecular switch in the phenotype of 
chondrocyte within a wound healing process [2]. In fact, 
downregulation of Cx43 in different wound healing and 
age-related disorders halts disease progression by 
restoring tissue regeneration [45–47].   
 
Oleuropein is the most abundant polyphenol in the 
leaves and fruit of the olive plant and is a potent 
antioxidant agent with anti-tumour and anti-
inflammatory properties [48, 49]. The mechanism of 
action of this polyphenol is under investigation [48]. 
Some studies showed that oleuropein and its major 
metabolite hydroxytyrosol have antioxidant activity by 
inhibition and/or scavenging of ROS [50], which can 
reduce NF-kB activation [51, 52]. Other mechanistic 
studies implicate nitric oxide (NO) production [53, 54] 
or autophagy and inhibition of the mammalian target of 
rapamycin (mTOR) [55, 56]. A gene expression 
profiling study has suggested that oleuropein affects the 
expression of genes involved in oxidative stress, 
inflammation, fibrosis, cell proliferation or 
differentiation [57], suggesting that the beneficial 
effects of this molecule may be multifactorial and 
context-dependent [57]. Innovative approaches based on 
functional foods have been recently studied and many 
beneficial effects of dietary olive oil on human health 
were already described [58–62]. In fact, extra virgin 
olive oil and olive leaf extract supplemented diets have 
been shown to reduce inflammation and preserve 
cartilage, muscle and joint function in rat preclinical 
models of OA [63–68].  
 
In this study, we have used a small-scale screening to 
identify compounds that downregulate Cx43. Here we 
describe the use of small molecules based on olive 
phenolic compounds to downregulate Cx43 in OA by 
using 2D and 3D human cartilage models. We have 
found that oleuropein decreases Cx43 promoter activity 
and GJIC, thus enhancing osteogenesis and 
chondrogenesis in hMSCs and redifferentiation of 
OACs. Beside downregulation of Cx43, olive-derived 
small polyphenols reduce cellular senescence in OACs, 
BC and SC, in addition to inflammatory and catabolic 




Olive-derived polyphenols impair adipogenesis and 
enhance the chondrogenic and osteogenic ability of 
hMSCs 
 
We used a small-scale screening to identify 
compounds that downregulate Cx43 (data not shown), 
and we identified the small molecule oleuropein 
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(Figure 1A). Oleuropein and an olive-extract (OE) 
significantly reduced Cx43 protein levels in OACs 
(Figure 1A). MTT assays showed no effect of 0.1-10 
µM oleuropein on cell viability of primary 
chondrocytes and hMSCs (Supplementary Figure 1). 
Based on these results and other studies [69], 10 µM 
was selected as the highest concentration with no toxic 
effect after 17 h in culture.  
 
We next examined hMSCs differentiation capacity in the 
presence of oleuropein (Figure 1B, 1C and Supplementary 
Figure 2). In accordance with previous results [69], 
oleuropein-treated hMSCs showed significantly less 
adipogenic differentiation ability, whereas osteogenesis 
was significantly increased (Figure 1B and 
Supplementary Figure 2A, 2B). Furthermore, a 3D 
micromass culture system using chondrogenic medium 
supplemented with 10 µM oleuropein or OE revealed 
increased ECM properties, reflecting a greater degree of 
chondrogenic differentiation, with higher levels of 
Col2A1 deposition and increased levels of aggrecan 
(ACAN) gene expression (Figure 1C and Supplementary 
Figure 2C). Remarkably, decreased Cx43 gene expression 
was detected in hMSCs during differentiation, mainly 
during chondrogenesis (Figure 1D, 1E and Supplementary 
Figure 3A). We have also observed changes in Cx43 
phosphorylation pattern at 7 and 14 days of chondrogenic 
differentiation (Figure 1D), which can affect Cx43 
stability and channel activity. Different Cx43 
phosphorylation patterns were also detected during 
adipogenesis and osteogenesis, suggesting differential 
regulation of Cx43 during hMSCs differentiation 
(Supplementary Figure 3B). The treatment of hMSCs 
during chondrogenic differentiation with oleuropein for 
14 days caused an additional 1.7 fold reduction in Cx43 
gene expression (Figure 1E). 
 
In concordance with these results, OACs’ 
redifferentiation for 7 days with oleuropein decreased 
Cx43 protein levels, but it did not affect its 
phosphorylation pattern (Figure 1F). However, we did 
not observe changes in the phosphorylation pattern 
when hMSCs or chondrocytes were treated with 
oleuropein (Figure 1F and Supplementary Figure 4A). 
 
It is important to note that these results were obtained 
during differentiation of hMSCs under osteogenesis or 
chondrogenesis (Figure 1B–1E) and dedifferentiated 
OACs in normal and in chondrogenic medium (Figure 
1A and 1F). However, the treatment of undifferentiated 
hMSCs cultured in basal growth medium with 
oleuropein/OE increased Cx43 levels (Supplementary 
Figure 4A and 4B) and GJIC (Supplementary Figure 
4C), indicating that the effect of these olive derived 
polyphenols may be different depending on the cellular 
context. 
Downregulation of Cx43 activity by oleuropein 
downregulates Twist-1 and enhances 
redifferentiation of OACs 
 
Oleuropein modulation of Cx43 significantly reduced 
GJIC in OACs (Figure 2A), but not in healthy 
chondrocytes (Figure 2B). The decrease in Cx43 and 
GJIC was correlated with a significant reduction in the 
levels of the stemness markers CD105 and CD166 
(Figure 2C). This result was consistent with our 
previous observations, where CD105 and CD166 were 
reduced when Cx43 was downregulated or when OACs 
were redifferentiated. In fact, oleuropein effectively 
improved the OACs phenotype, detected by the increase 
of Col2A1 levels and the decrease of proinflammatory 
mediators and MMP-3 levels (Figure 2D, 2E). 
Oleuropein treatment reduced overall Cx43 positivity, 
increased Col2A1 levels (Figure 2D) and decreased 
interleukin 6 (IL-6), COX-2, IL-1ß and MMP-3 gene 
expression (Figure 2E) and protein levels (Figure 2F).  
 
Next, we sought to confirm whether oleuropein would 
target chondrocyte plasticity in 3D cultures. Treatment 
of OACs grown as a 3D culture in chondrogenic 
medium with oleuropein increased the deposition of 
proteoglycans and Col2A1 (Figure 3A), improving the 
ECM structure by decreasing Cx43 levels (Figure 3B). 
 
To explore the effect of oleuropein on cell plasticity, 
OACs were grown in adipogenic medium supplemented 
with oleuropein, which significantly decreased their 
adipogenic differentiation (Figure 3C). However, 
oleuropein promoted osteogenesis when OACs were 
grown in osteogenic medium supplemented with 10 µM 
of oleuropein  (Supplementary Figure 5).  
 
Upregulation of Cx43 in OA involves dedifferentiation 
via chondrocyte-to-mesenchymal transition by Twist-1 
activation, which was also reported in OA cartilage [2, 
70, 71]. OACs were treated with the arthritic insult 
oligomycin, which induces cellular ROS production and 
cartilage degradation [72, 73]. After oleuropein 
treatment, OACs showed a significant reduction in the 
nuclear localization of Twist-1 (Figure 3D). Nuclear 
localization of Twist-1 in the presence of oligomycin 
was attenuated when Cx43 protein levels were reduced 
by oleuropein treatment of OACs (Figure 3E). In 
addition, oleuropein treatment in OACs reduced the 
expression of the mesenchymal and EMT markers N-
cadherin and vimentin (Figure 3F). 
 
Oleuropein modulates Cx43 gene promoter activity  
 
In chondrocytes, decreased Cx43 protein levels were 
detected when OACs and the T/C-28a2 cell line were 
treated with oleuropein (Figures 1A and 4A). However, 
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Figure 1. Downregulation of Cx43 during chondrogenesis improves differentiation towards chondrocytes. (A) Treatment of 
OACs with oleuropein (Oleu) or olive extract (OE) for 2 h significantly downregulates Cx43 protein detected by western-blot and flow 
cytometry.  Median fluorescence intensity (MFI) ratios of oleuropein and OE treatments with respect to their untreated controls of each 
experiment are represented (n=10 independent experiments, P=0.0003). (B) Differentiation capacity of hMSCs isolated from bone marrow 
grown in adipogenic (top, 21 days) or osteogenic (bottom, 21 days) medium supplemented with 10 µM oleuropein or 10 µM OE. hMSCs 
cultured in growth medium were used as a control. Top, adipogenic evaluation by oil red O for lipid staining and by PPARγ gene expression. 
Data represent the ratio of cells containing lipid deposits to the total number of cells (n=3 independent experiments, P<0.0001). Values were 
normalized to hMSCs differentiated in adipogenic medium without treatment (AM). On the right, PPARγ gene expression (n=4 independent 
experiments, P<0.0001). Alizarin red staining was used to detect calcium deposits for osteogenic differentiation. Values were obtained by 
counting red pixels and normalized to those of hMSCs differentiated in osteogenic medium without treatment (OM) (n=4-6 independent 
experiments, P=0.0317). OSTCN gene expression was measured to confirm osteogenic differentiation (n=4 independent experiments, 
P=0.0055). (C) Differentiation capacity of hMSCs isolated from bone marrow grown in chondrogenic medium as micromasses for 30 days. 
Representative images for Col2A1. The quantification is shown on the right (n=5–6 micromasses from independent experiments, P=0.0423). 
Chondrogenesis was also evaluated by ACAN gene expression quantification (n=3–4 independent experiments, P<0.0001). (D) Cx43 protein 
levels in hMSCs, isolated from bone marrow and from inguinal fat, differentiated for 7 and 14 days in the presence of chondrogenic medium 
(CM) in comparison to untreated hMSCs cultured in normal growth medium (GM). (E) Cx43 RNA expression of hMSCs cultured for 14 days in 
the presence of chondrogenic medium (CM) alone or supplemented with 10 µM oleuropein. Data were normalized to HPRT-1 levels (n=5-6 
independent experiments, P<0.0001). (F) Cx43 protein levels were analyzed by western blot in OACs differentiated for 7 days in the presence 
of chondrogenic medium (CM), supplemented with 10 µM oleuropein. The graph represents the quantification from 3 independent 
experiments (P=0.0004). Data is expressed as mean±SD, one-way ANOVA; *P<0.05, **P<0.01 and ***P<0.0001. 
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Figure 2. Downregulation of Cx43 by oleuropein decreases GJIC and improves the phenotype of OACs. (A) Oleuropein (Oleu) 
treatment significantly decreases GJIC evaluated by an SL/DT assay when OACs were exposed with this molecule for 2 h (top, n=6 
independent experiments; Student’s t test, P<0.0001). The results were confirmed by calcein transfer by flow cytometry (n=4 independent 
experiments; Student’s t test, P=0.0037). (B) Graph showing the effect of oleuropein on GJIC when healthy chondrocytes (N) were exposed to 
10 µM oleuropein compared with OACs (n=5 independent experiments; one-way ANOVA, P=0.0004). (C) OACs cultured for 7 days with 10 µM 
Oleu showed reduced expression of the mesenchymal markers CD105 and CD166, analyzed by flow cytometry. Student’s t test, P=0.0039 
(CD105) and P=0.0022 (CD166), n=6 independent experiments. CD166 levels were also analyzed by western blot (n=3 independent 
experiments, Student’s t test, P=0.0046). (D) Downregulation of Cx43 increased Col2A1, detected by immunofluorescence in OACs treated 
with 10 µM oleuropein. Graphs represent the corrected total cell fluorescence (CTCF) of Cx43 and Col2a1 (n=4 independent experiments). 
Student’s t test, P<0.0001 (Cx43), and P=0.0007 (Col2a1). (E) mRNA levels of IL-1ß, IL-6, COX-2 and MMP-3 of OACs cultured in normal 
medium (UT) exposed to 10 µM oleuropein for 2 h. n=4–7 independent experiments. Student’s t test: P= 0.033 (IL-1ß), P<0.0001 (IL-6), 
P=0.1013 (COX-2), P=0.0466 (MMP-3). (F) IL-6 detected by ELISA when OACs were treated with oleuropein for 72 h (n=4 independent 
experiments, Student’s t test, P=0.0345). IL-6 (n=3 independent experiments) and COX-2 (n=4 independent experiments) protein levels 
detected by western-blot in OACs treated with 10 µM oleuropein for 72 h. Student’s t test, P=0.0193 (IL-6), P=0.0141 (COX-2). Data is 
expressed as mean±SD; *P<0.05, **P<0.01 and ***P<0.0001. 
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these changes were not evident in treated Cx43-
overexpressing T/C-28a2 chondrocytes (Figure 4A, 
bottom), suggesting that oleuropein may affect Cx43 
gene promoter activity rather than protein stability. We 
thus measured whether oleuropein affected the activity 
of the Cx43 gene promoter using a real-time reporter 
system. T/C-28a2 chondrocytes were transfected with a 
firefly luciferase reporter vector containing the 
regulatory regions of the Cx43 promoter and incubated 
for 1 h with oleuropein and the mitochondrial inhibitor 
oligomycin, which enhanced Cx43 gene expression 
(Figures 3E, 4B). Cx43 promoter activity decreased 
after oleuropein treatment (Figure 4B), while 
oligomycin increased the luminescence signal, and the 
effect of oligomycin was significantly attenuated in the 
presence of oleuropein (Figure 4B), which was 
correlated with Cx43 gene expression (Figure 4B). 




Figure 3. Oleuropein treatment enhances chondrocyte redifferentiation. (A) Immunohistochemistry of Col2A1 (4-6 independent 
experiments; one-way ANOVA, P=0.0019) and toluidine blue staining of proteoglycan subunits (n=6 independent experiments; one-way 
ANOVA, P=0.059) indicate significant enrichment in ECM components in OACs micromasses grown in 3D culture for 30 days in chondrogenic 
medium (CM) when supplemented with 10 µM oleuropein (Oleu) or OE. (B) Cx43 protein levels detected by western blot (and normalized to 
Ponceau staining) are reduced when OACs micromasses are exposed to CM supplemented with 10 µM oleuropein or OE for 21 days (n=3 
independent experiments; one-way ANOVA, P=0.0328). (C) Oil red staining showing reduced OACs dedifferentiation upon exposure to Oleu 
or OE in adipogenic medium (n=5 independent experiments; one-way ANOVA, P=0.0001). (D) Nuclear levels of Twist-1 were decreased in 
OACs cultured with 10 µM oleuropein for 2 h. Lamin A was used as a loading control (n=3 independent experiments; Student’s t test, 
P=0.001). (E) Cx43 protein levels in primary OACs after 1-h treatment with oleuropein or oligomycin. Western blot represents n=4 
independent experiments. Quantification is shown on the right (one-way ANOVA, P=0.0036). On the right, immunofluorescence for Twist-1 
(red) in primary OACs treated with 5 µg/ml oligomycin and 10 µM oleuropein for 1 h. The graph represents the percentage of cells with 
Twist-1 nuclear localization (n=4 independent experiments; one-way ANOVA, P=0.0067). (F) The mRNA expression of the EMT markers Twist-
1, N-Cadherin and Vimentin in OACs treated with 10 µM oleuropein for 2 h. Data were normalized to HPRT-1 levels. n= 5 independent 
experiments; Student’s t test: P<0.0001 (Twist-1), P= 0.0011 (N-Cad), P=0.0209 (Vim). Data is expressed as mean±SD; *P<0.05, **P<0.01 and 
***P<0.0001.  
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of oleuropein and oligomycin on protein levels (Figures 
3E and 4C). These results indicate that oleuropein 
affects Cx43 gene promoter activity, thus 
downregulating Cx43 protein levels (Figure 1A and 
Figure 4A–4C) and GJIC in OACs (Figure 2B). 
 
Oleuropein enhances elimination of senescent cells 
 
Senescent cells through their secretory activity (SASP) 
can promote dedifferentiation and reprogramming in 
neighboring cells in the context of tissue injury [74]. 
OACs treated with 10 µM oleuropein for 7/14 days in 
growth medium showed a significant reduction of 
senescent cells accumulated after 5 days of primary 
culture (Figure 5A). Consistent with these models, 
Cx43 upregulation due to the oligomycin insult 
significantly contributed to increase cellular senescence 
in OACs accumulated after 5 days in monolayer (Figure 
5B, left), whereas co-treatment with oleuropein 
significantly halted the accumulation of senescent cells 
after 24 h (Figure 5B, left) and 7 days under treatment 
(Figure 5B, right). Interestingly, increased SA-βGal 
activity was detected when the T/C-28a2 chondrocytes 
were treated with bleomycin to induce cellular 
senescence for 24 h, while the exposure to oleuropein 
for 24 h reduced the number of senescent cells 
(Supplementary Figure 6B). In accordance with these 
results, treatment of OACs with oleuropein led to 
decreased levels of the senescence biomarkers p16INK4A 




Figure 4. Oleuropein modulates the Cx43 promoter activity in chondrocytes. (A) Treatment with 10 µM oleuropein for 2 h 
decreases Cx43 protein levels in T/C-28a2 cells (n=4 independent experiments, Student’s t test, P=0.0012), but this effect was not observed 
in the same cell line overexpressing Cx43 (pIRES-Cx43)(n=3 independent experiments, Student’s t test, P=0.0624). (B) Luciferase reporter 
assay indicating that oleuropein inhibits Cx43 promoter activity. The graphs indicate the normalized luminescence activity in the T/C-28a2 
transfected with a pGL3-basic plasmid containing 300 base pairs of Cx43 promoter ligated to the luciferase gene. Cells were cultured in 
DMEM with 10% FBS (UT) and with 5 µg/ml oligomycin or 10 µM oleuropein for 1 h as indicated (n=4 independent experiments; one-way 
ANOVA, P=0.0012). On the right, Cx43 gene expression under 5 µg/ml oligomycin and 10 µM oleuropein treatment in OACs treated for 1 h 
(n=4 independent experiments; one-way ANOVA, P=0.0002). Data were normalized to HPRT-1 levels. (C) Immunofluorescence assays of Cx43 
in  OACs treated with 10 µM oleuropein or 5 µg/ml oligomycin for 1 h. Data were normalized to the untreated condition (n=3 independent 
experiments; one-way ANOVA, P<0.0001). Data is expressed as mean±SD; *P<0.05, **P<0.01 and ***P<0.0001. 
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proliferative arrest observed after the treatment of T/C-
28a2 healthy chondrocytes with the Cyclin-Dependent 
Kinase 4/6 inhibitor palbociclib to induce senescence 
was partially inhibited by the co-treatment with 
oleuropein (Figure 5E). Oleuropein reduced the 
accumulation of senescent cells and attenuated the 
oligomycin-induced SASP secretion detected by IL-6, 
COX-2 and IL-1ß gene expression in chondrocytes 
(Figure 5F). The SASP, including IL-6 gene expression, 
can be activated by NF-κB [75]. Oleuropein protected 
from the increase of Cx43 under TNFα treatment 
(Figure 5G, left), and NF-κB (p65) activation by TNFα 
in OACs was diminished when cells were exposed to 
oleuropein for 1 h (Figure 5G). Further, NF-κB nuclear 
translocation was partially abolished in OACs treated 
with oleuropein for only 2 h (Figure 5H).   
 
To further test the senolytic activity of oleuropein, SC 
and BC from OA patients were treated with oleuropein 
(Figure 6). We observed decreased Cx43 protein levels 
after oleuropein exposure (Figure 6A and 6D), together 
with a significant reduction in senescent cells 
accumulated after 5 days in primary culture (Figure 6B 
and 6E), confirmed by p16INK4A gene expression and the 
synthesis of the SASP factors IL-1ß, COX-2 and IL-6 




Previous data from our group demonstrate that Cx43 
downregulation improves the chondrocyte phenotype, 
protecting chondrocytes from dedifferentiation and 
senescence [2]. Although oleuropein and olive-based 
diets were reported to protect from OA progression [76, 
77], there was no solid evidence about its underlying 
molecular mechanisms. In our study, we show that 
oleuropein modulates Cx43 gene promoter activity, 
reducing Cx43 and GJIC in OACs. Indeed, our data 
indicate that Cx43 downregulation by oleuropein in 
OACs improves cell phenotype by protecting 
chondrocytes from Twist-1 activation and from 
accumulation of senescent cells (Figures 2, 3, 5 and 6). 
This is the first study that demonstrated one of the 
potential mechanisms of oleuropein in OACs, SC and 
BC (Figures 5 and 6) from patients, and in hMSCs 
(Figure 1), with relevant applications in regenerative 
medicine.  
 
Our results show that the effects of oleuropein are often 
equal or even smaller than those of the olive extract, 
suggesting that other compounds may synergize with 
oleuropein activity in chondrocytes [78]. On the other 
hand, the treatment of hMSCs with oleuropein or OE 
during differentiation leads to downregulation of Cx43 
and GJIC, enhancing osteogenesis and chondrogenesis, 
but reducing adipogenesis. This differential sensitivity 
of hMSCs to oleuropein and OE may have potential 
applications in preventive and regenerative medicine in 
other bone and cartilage disorders.  
 
Our data show decreased Cx43 and GJIC levels in the 
presence of oleuropein in OACs and in differentiating 
hMSCs, but increased Cx43 and GJIC levels in 
undifferentiated hMSCs, suggesting that the effect of this 
molecule on GJIC depends on its effect on Cx43 levels 
(or subcellular localization). In fact, phosphorylation of 
Cx43 affects protein stability and GJIC activity [79] and 
we have detected changes in Cx43 phosphorylation 
pattern during hMSCs differentiation but not under 
oleuropein treatment indicating that oleuropein affects 
Cx43 levels more than gap junction plaque activity or 
modulation. We cannot therefore discard that the effect 
of oleuropein may also depend on channel-independent 
activities, which involve the signaling hub’s ability of 
Cx43 to recruit proteins to the membrane [34, 80, 81] or 
its ability to control gene transcription [82]. It is 
important to note that oleuropein may have other targets 
that may contribute to the drug effect. Despite this 
limitation and based on our results, we expect that the 
effect of oleuropein occurs at least partially through Cx43 
modulation. Here, we show that oleuropein restores 
chondrocyte phenotype detected by reduced levels of the 
stem-markers CD105, CD166, N-cad and vimentin 
(Figure 2C, 3F). The effect of oleuropein in chondrocyte 
plasticity correlated with activation of redifferentiation 
via downregulation of Cx43 and Twist-1 (Figure 3D–3F), 
leading to increased levels of proteoglycans and Col2A1 
together with decreased levels of inflammatory cytokines 
and metalloproteinases (Figures 2D–2G, and 3A).  
 
In cell culture and in cartilage, OACs undergo 
dedifferentiation and senescence [2, 18, 20]. 
Elimination of senescent cells in vivo using the 
senolytic drug UBX0101 has been demonstrated to 
improve cartilage regeneration after articular joint 
injury in mice [1]. Here we show that oleuropein 
reduces cellular senescence in OACs, SC and BC and 
protects from accumulation of senescent cells under an 
arthritic insult (Figures 5A, 5B, 6B and 6F). NF-kB has 
been shown to regulate the inflammatory components of 
the SASP, together with other factors [83, 84]. In this 
study the reduction of senescence is accompanied by 
reduced NF-kB activity, and therefore reduced synthesis 
of SASP (Figure 5F). Notably, these components 
enhance inflammation, senescence and activate 
dedifferentiation and cellular reprogramming of nearby 
non-senescent cells (e.g. via IL-6) [74], contributing to 
the stem-like state of chondrocytes in OA and to the 
accumulation of senescent cells. Accordingly, we have 
previously reported that upregulation of Cx43 leads to 
p53/p16 upregulation and senescence [2]. Using the 
T/C-28a2 cells with a Cx43 overexpression vector and a 
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CRISPR/Cas9-mediated heterozygous Cx43 gene 
knockdown cell line we have demonstrated that Cx43 is 
an upstream effector of both senescence (involving p53 
and p16 pathways) and NF-kB activation [2]. 
Cellular reprogramming, dedifferentiation via EMT and 
senescence play active roles during tissue regeneration 
[85, 86]. Accumulation of dedifferentiated (stem-like 




Figure 5. Cx43 downregulation by oleuropein decreased chondrocyte senescence. (A) SA-βGal activity detected by flow cytometry 
in OACs treated with 10 µM oleuropein (Oleu) for 7 and 14 days (n=3–7 independent experiments; one-way ANOVA, P<0.0001). (B) The 
graphs show the comparative analysis of SA-βGal activity measured by flow cytometry of OACs exposed for 24 h to 10 µM oleuropein or 5 
µg/ml oligomycin as indicated (n=5 independent experiments; one-way ANOVA, P=0.0003). On the right, SA-βGal activity determined by X-
Gal cleavage and cell staining (blue), evaluated by microscopy in OACs treated for 7 days with 10 µM oleuropein or 5 µg/ml oligomycin (n=3 
independent experiments; one-way ANOVA, P<0.0001). (C) p16 mRNA expression of OACs treated with 10 µM oleuropein for 2 h. Data were 
normalized to HPRT-1 levels (n=5 independent experiments; Student’s t test, P=0.0002). (D) Western blot of p53 (n=3 independent 
experiments), p21 (n=3 independent experiments) and p16 (n=4 independent experiments) in OACs treated with 10 µM oleuropein for 2 h. α-
tubulin was used as a loading control. Student’s t test, P=0.001 (p53), P=0.0278 (p21), P=0.0286 (p16). (E) Cell proliferation evaluated by 
immunofluorescence of Ki-67 in T/C-28a2 chondrocytes treated with 10 µM palbociclib and/or 10 µM oleuropein for 24 h. Images represent 
n= 3 independent experiments. One-way ANOVA, P=0.0434 (UT vs Palbo); P=0.0096 (Palbo vs Palbo+Oleu). (F) Downregulation of Cx43 by 
oleuropein attenuates IL-6 and COX-2 upregulation when OACs are exposed to oligomycin for 1 h (n=3–9 independent experiments; one-way 
ANOVA). (G) Western blot (n=3 independent experiments) shows the effect of 10 µM oleuropein and 10 ng/mL TNFα treatments (for 1 h) on 
Cx43 protein levels in OACs (one-way ANOVA, P=0.0018). On the right, NF-κB detected by immunofluorescence in OACs treated with 10 
ng/mL TNFα for 1 h. This effect is partially abolished by 1-h 10 µM oleuropein treatment. The graph represents the cell percentage with 
nuclear NF-κB staining (n=7 independent experiments; one-way ANOVA, P=0.0055). (H) Nuclear levels of NF-kß in OACs cultured with 10 µM 
oleuropein for 2 h. Lamin A was used as a loading control (n=3 independent experiments; Student’s t test, P=0.0021). Data is expressed as 
mean±SD; *P<0.05, **P<0.01 and ***P<0.0001. 
 
www.aging-us.com 15891 AGING 
regeneration and fibrosis with loss of tissue function 
[87] (Figure 7). Understanding and manipulating the 
complex Cx43 signaling would expand our 
opportunities for modulating wound-healing related 
disorders such as OA. So far, our results indicate that 
molecules that reduce Cx43 levels in OA, including 
oleuropein, will potentially contribute to create a 
regeneration-permissive environment in OA patients. 
 
Our preliminary study is the first to demonstrate the 
effect of this polyphenol on Cx43 activity and 




Figure 6. Oleuropein treatment decreased cellular senescence in synoviocytes and bone cells isolated from patients. (A) Cx43 
protein levels analyzed by western blot in synoviocytes treated with 10 μM oleuropein for 2 h (n=7 independent experiments, P=0.0313).  
(B) Treatment of synoviocytes with 10 μM of oleuropein for 7 days detected by SA-βGal activity (n=4 independent experiments, P<0.0001). 
(C) p16 mRNA levels of synoviocytes treated with 10 μM oleuropein for 2 h. Data were normalized to HPRT-1 levels (n= 4 independent 
experiments, P<0.0001). On the right, mRNA levels of IL-1ß, IL-6 and COX-2 of synoviocytes cultured in normal medium (DMEM 10% FBS) and 
exposed to 10 μM oleuropein for 2 h. Data were normalized to HPRT-1 levels. N=4 independent experiments, P<0.0001 (IL-1ß), P=0.0024 (IL-
6), P=0.0025 (COX-2). (D) Cx43 protein levels analyzed by western blot in bone cells treated with 10 μM oleuropein for 2 h (n=4 independent 
experiments, P=0.0319). (E) 10 μM of oleuropein treatment for 7 days reduces senescence levels in bone cells as detected by SA-βGal and 
flow cytometry (n=3 independent experiments, P=0.0149). (F) p16 mRNA expression of bone cells treated with 10 μM oleuropein for 2 h. 
Data were normalized to HPRT-1 levels (n= 4 independent experiments, P=0.002). On the right, mRNA levels of IL-1ß, IL-6 and COX-2 of bone 
cells cultured in normal medium (DMEM 10% FBS) exposed to 10 μM oleuropein for 2 h. Data were normalized to HPRT-1 levels. N=3-4 
independent experiments. P=0.0463 (IL-1ß), P=0.0077 (IL-6), P=0.0002 (COX-2). Data is expressed as mean±SD, Student’s t test; *P<0.05, 
**P<0.01 and ***P<0.0001. 
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shifts the hMSCs differentiation capacity towards 
osteogenic and chondrogenic lineages, while decreasing 
adipogenic differentiation. It is important to remark that 
aging has been reported to reduce the reparative 
potential of MSCs [31]. Hence, the use of small 
polyphenols such as oleuropein may be useful in cell 
therapy approaches that aim to promote cartilage and 
bone regeneration, as the osteogenesis/adipogenesis 
switch has been associated with different bone disorders 
[88, 89]. Altogether, these findings indicate that 
oleuropein controls Cx43 gene expression and acts as a 
senolytic drug that may serve as a potential agent to 
improve both the effectiveness of stem cell therapy and 
cartilage and joint regeneration in patients to stop OA 
progression. Thus, the implementation of therapies 
based on Cx43 modulators or innovative approaches 
based on functional foods enriched in olive extracts may 
improve joint functions and quality of life for OA 





Figure 7. Cx43 overactivity contributes to disease progression. Cx43 overexpression leads to accumulation of dedifferentiated and 
senescent cells involved in disease progression in OA patients. These phenotypic changes results in the synthesis of ECM remodeling factors 
involved in tissue degradation (MMPs) and proinflammatory factors, such as IL-1ß and IL-6, which facilitate the dedifferentiation and 
reprogramming of neighboring cells. These factors may further spread senescence and dedifferentiation to surrounding tissues contributing 
to joint degeneration. Downregulation of Cx43 by oleuropein treatment contributes to the elimination of senescent cells and 
redifferentiation of osteoarthritic chondrocytes into fully differentiated cells, able to support the ECM composition and restoring the 
regenerative capacity of the tissue. However, oleuropein may have other targets that may contribute to the drug effect. In addition, 
oleuropein treatment might improve the effectiveness of stem cell therapy, by promoting chondrogenic and osteogenic differentiation, and 
by inhibiting adipogenesis. 
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MATERIALS AND METHODS 
 
Tissue collection, processing and cell culture 
 
Collection and processing of cartilage from human 
knees and femoral heads from adult donors undergoing 
joint surgery were performed as previously described 
[10]. Briefly, primary chondrocytes were isolated from 
cartilage by mechanical (dicing) and enzymatic 
digestion, with an incubation with 0.5 mg/mL of 
trypsin-EDTA (Gibco, Thermo Fisher Scientific) for 10 
min at 37ºC, followed by an overnight incubation at 
37ºC with a 2 mg/mL collagenase IV solution, with 
shaking. Finally, digested cartilage was filtered through 
a 100 µm strainer and chondrocytes were seeded onto 
100 mm dish plates (Corning, Sigma-Aldrich). The 
study was conducted with the approval of the 
institutional ethics committee (C.0003333, 2012/094 & 
2015/029) after the acquisition of signed informed 
consents. We have collected cartilage samples (1 
sample per patient) from a total amount of 22 donors 
(14 OA donors and 8 healthy donors) from hip and knee 
joints with a mean age of 72.1±4,7 years (50% women 
and 50% men) within OA donors, and a mean age of 
81.62±2.9 years (75% women and 25% men) within 
healthy donors. Cartilage samples from healthy donors 
were obtained after knee or hip fracture with no history 
of joint disease. All samples (healthy and OA) were 
analyzed by histological staining and classified 
following the American College of Rheumatology 
(ACR) recommendations and clinical classification 
criteria for OA. The chondrocyte cell line T/C-28a2 was 
kindly donated by Dr. Goldring (Hospital for Special 
Surgery; New York, USA). Primary chondrocytes and 
T/C-28a2 cells were cultured in Dulbecco’s Modified 
Eagle’s medium (DMEM) supplemented with 100 
U/mL penicillin, 100 µg/mL streptomycin and 10% 
foetal bovine serum (FBS). Human mesenchymal stem 
cells (hMSCs) were obtained with signed informed 
consent from 4 bone marrow donors (Hospital 
Universitario Reina Sofía; Córdoba, Spain) and from 
subcutaneous inguinal fat from 2 healthy individuals 
(Hospital Universitario Ramón y Cajal; Madrid, Spain). 
hMSCs were cultured in MesenPRO RSTM Medium 
supplemented with 100 U/ml penicillin and 100 µg/ml 
streptomycin. Synoviocytes (cultured in RPMI 10%FBS 
supplemented with 1% insulin-transferrin-selenium, 100 
U/mL penicillin and 100 µg/mL streptomycin) and bone 
cells (cultured in DMEM supplemented with 100 U/mL 
penicillin, 100 µg/mL streptomycin and 20% 
inactivated FBS) from OA patients were donated by 
Raquel Largo (IIS-Fundación Jiménez Díaz; Madrid, 
Spain), after signed informed consent. hMSCs, primary 
chondrocytes, T/C-28a2 cells, BC and SC at 70-80% 
confluence were treated with oleuropein (Extrasynthese 
#0204; Lyon, France) or an olive extract (OE) 
containing 41.5% of oleuropein, donated by the Clinical 
Management Unit of Endocrinology and Nutrition 
(IMIBIC, Córdoba, Spain). OE was dissolved in culture 
medium to a stock concentration equivalent to 100 µM 
oleuropein. Both compounds were dissolved in the cell 
culture medium and added to the cells for short-term 
(1–2 h) or long-term (7–14—21 days; each 48 hours) 
treatments. Bone cells and synoviocytes were treated 
with oleuropein 10 µM for 2 h at a 70% confluence. For 
cell treatments, chondrocytes at a 70-80% confluence 
were treated for 1 h with either 5 µg/ml oligomycin 
(Sigma-Aldrich) or 10 ng/mL TNFα (Immunotools). In 
addition, these cells were also treated simultaneously 
for 1 h with the combination of oligomycin or TNFα 
with 10 µM oleuropein. Cell proliferation arrest in T/C-
28a2 healthy chondrocytes was performed by a 24h-
treatment with 10 µM of Palbociclib (APExBIO) or the 
combination of Palbociclib and 10 µM oleuropein. 
 
Cell viability assay 
 
Cells at a 75% confluence were treated with 0.1 µM, 1 
µM, 10 µM and 10 mM oleuropein for 17 h. Drug 
cytotoxicity was evaluated by the colorimetric MTT 
assay (Cell Proliferation Kit I, Roche) with a 





Adipogenic differentiation was performed as previously 
described [2]. Cells were incubated with adipogenic 
medium (hMSC Adipogenic Differentiation BullekitTM, 
Lonza) for 21 days, with the addition of oleuropein or 
OE. Adipogenic differentiation was evaluated by the 




For osteogenic differentiation, cells were differentiated 
for 21 days with osteogenic medium (StemPro® 
Osteogenesis Differentiation Kit, Gibco, Thermo Fisher 
Scientific), with the addition of oleuropein or OE. 
Osteogenesis was evaluated by the RNA expression of 




Chondrogenesis was performed in OACs and hMSCs as 
cell micromasses (3D) or as a monolayer culture. For the 
3D culture, 500000 cells were seeded in non-adherent 
conic tubes and centrifuged at 500 xg for 10 min, resulting 
in a pellet formation, and cultured in chondrogenic 
medium (CM; StemPro® Chondrogenesis Differentiation 
Kit, Gibco, Thermo Fisher Scientific) supplemented with 
oleuropein or OE for 30 days. For the monolayer culture, 
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cells were differentiated in CM for 7/14 days with 
oleuropein/OE addition. Chondrogenesis was evaluated 
by proteoglycans detection (toluidine blue staining), 
Col2A1 immunohistochemistry and by ACAN mRNA 
expression.  
 
Scrape loading/dye transfer (SL/DT) assay 
 
Confluent cells were treated with oleuropein or OE for 
2 h. Next, a 0.4% (w/v) solution of lucifer yellow (LY) 
(Cell Projects Ltd©) was loaded and two distant scrapes 
were made across the culture plate. In order to evaluate 
GJIC, a score was calculated as the ratio of non-damage 
positive cells for LY to the damaged cells [2, 10].  
 
GJ connectivity by flow cytometry 
 
Equal numbers of cells were incubated for 1 h at 37 ºC 
with either 1 µM of the membrane dye DiI (Invitrogen, 
Thermo Fisher Scientific) or 1 µM calcein-AM 
(Invitrogen, Thermo Fisher Scientific), a cell-permeable 
dye that is retained in the cytosol and can be transferred 
by GJs. Then, cells were washed with PBS and co-
cultured for 2 h in a 1:4 ratio (calcein-donors:DiI-
recipient cells). The percentage of DiI+Calc+ cells was 




Protein analysis was performed as previously described 
[2, 10]. The following primary antibodies were used: α-
tubulin (Sigma-Aldrich, T9026), Cx43 (Sigma-Aldrich, 
C6219), Twist-1 (Santa Cruz Biotechnology, sc-81417), 
CD166 (Santa Cruz Biotechnology, sc-74558), p16INK4A 
(Abcam, ab108349), p21 (Santa Cruz Biotechnology, 
sc-6246), p53 (Santa Cruz Biotechnology, sc-126), NF-
κB (Santa Cruz Biotechnology, sc-8008), lamin A 
(Santa Cruz Biotechnology, sc-20680), IL-6 (Sigma-
Aldrich, SAB1403971) and COX-2 (Santa Cruz 
Biotechnology, sc-166475). 
 
Enzyme-linked immunosorbent assay (ELISA) 
 
Supernatants were collected after a 72 h-treatment with 
oleuropein 10 µM, and diluted in a 1:8 ratio prior to the 
measurement. Samples were incubated for 2 h at room 
temperature, and IL-6 was detected using the 
quantitative sandwich human IL-6 immunoassay (hIL-
6-EIA-20, MagTag GmbH). Samples were analyzed at 
450 nm in a TECAN plate reader. 
 
Antigen expression analysis by flow cytometry 
 
Paraformaldehyde-fixed cells were incubated with 
phycoerythrin (PE)-conjugated anti-human CD105 
(Immunostep, 105PE-100T) or allophycocyanin (APC)-
conjugated anti-human CD166 (Immunostep, 
1399990314), for 30 min at 4°C, as previously reported 
[2] (Supplementary Table 1). Intracellular Cx43 protein 
was detected in paraformaldehyde-fixed cells after 
permeabilization with methanol for 30 min at 4ºC. 
Finally, cells were incubated with APC-conjugated anti-
human Cx43 antibody (R&D Systems, FAB7737A) for 
30 min at 4°C. 
 
Flow cytometry analysis 
 
20.000 events were collected on a FACSCaliburTM 
(Becton Dickinson) flow cytometer with the CellQuestTM 
Pro software. Cell debris was discriminated by the 
forward scatter (FSC) and side scatter (SSC) properties of 
the cells. Data were analyzed with FCS Express 6 Flow 
software (De Novo Software). The level of positive 
staining was expressed as the median fluorescence 
intensity (MFI), with unlabelled cells as negative controls. 
Gates were placed based on single-labelled controls and 
by establishing 0.1% as the cut-off point. 
 
Senescence-associated β-galactosidase activity 
 
Flow cytometry analysis of SA-βGal activity with the 
fluorogenic β-galactosidase substrate fluorescein di-β-
D-galactopyranoside (FDG; Invitrogen, Thermo Fisher 
Scientific) was performed as previously described [2]. 
Briefly, cells were harvested and incubated with pre-
warmed 2 mM FDG for 3 min at 37 ºC and fluorescein 
positivity was analyzed on a BD FACSCaliburTM 
(Becton Dickinson) flow cytometer. SA-βGal activity 
was also measured with the Senescence Cells 
Histochemical Staining Kit (Sigma-Aldrich) according 
to the manufacturer’s protocol and analyzed after 16 h 
of staining. 
 
Immunofluorescence and immunohistochemistry 
 
Immunofluorescence and immunohistochemistry assays 
were performed as previously described [2, 10]. The 
following primary antibodies were used: anti-Cx43 
(Sigma-Aldrich, C6129), anti-collagen II (Invitrogen, 
Thermo Fisher Scientific, MA5-12789), anti-Ki-67 
(BD, 550609), anti-Twist-1 (sc-81417) and anti-NF-κB 
(sc-8008) from Santa Cruz Biotechnology. Goat anti-
rabbit FITC-conjugated (F-2765, Invitrogen, Thermo 
Fisher Scientific) and goat anti-mouse Alexa 594-
conjugated (A-11032, Invitrogen, Thermo Fisher 




TRIzolTM reagent (Invitrogen, Thermo Fisher Scientific) 
was used to isolate total RNA, according to the 
manufacturer's instructions. 1 µg of total RNA per 
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reaction was used to synthesize cDNA with the 
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen, 
Thermo Fisher Scientific). Quantitative PCR was 
performed as previously described [2, 10]. Primers are 




Cx43 was overexpressed, as previously described [2], in 
the T/C-28a2 chondrocyte cell after transfection with a 
pIRESpuro2 plasmid construct (Clontech) containing the 
human Cx43 sequence, kindly provided by Arantxa 
Tabernero (INCL, University of Salamanca, Spain). 
Electroporation was performed with the Amaxa® Cell 
Line Nucleofector® Kit V (Lonza) in a NucleofectorTM 
2b device (Lonza) following the manufacturer’s 
instructions. 
 
Luciferase reporter assay 
 
A DNA construct containing the upstream 300 bp-
regulatory sequence of the human Cx43 promoter (–
108, +279, relative to the human Cx43 transcription 
start site) in a pGL3-Basic vector was kindly donated by 
Dr. Mustapha Kandouz (Wayne State University, USA). 
The T/C-28a2 chondrocyte cell line was transfected 
with the Amaxa® Cell Line Nucleofector® Kit V in a 
NucleofectorTM 2b device. After 24 h, cells were treated 
with 10 µM oleuropein and/or 5 µg/ml of oligomycin 
(Sigma-Aldrich) for 1 h. For the luminescence analysis, 
the Firefly Luciferase Assay Kit from Biotium was used 
according to the manufacturer’s instructions, and 




Statistical analysis was performed with GraphPad Prism 
software (version 7.0a). Data of the biological and/or 
technical replicates are represented as mean and SD. 
Two-tailed Unpaired Student’s t test was used to 
estimate statistically significant differences between 
two groups. The estimation of the difference of the 
means among groups was compared by one-way 
ANOVA with Bonferroni correction. P values were 
provided, with P<0.05 considered as statistically 




ACAN: aggrecan; AM: adipogenic medium; BC: bone 
cells; CBX: carbenoxolone; CD105: endoglin; CD166: 
CD166 antigen (ALCAM); CM: chondrogenic medium; 
CMT: chondrocyte-to-mesenchymal transition; Col2A1: 
collagen type II; COX-2: cyclooxygenase-2; Cx43: 
connexin43; CxREs: connexin-response elements; ECM: 
extracellular matrix; EMT: epithelial-to-mesenchymal 
transition; FDG: fluorescein-di-D-galactopyranoside; GJs: 
gap junctions; GJIC: gap junction intercellular 
communication; hMSCs: human mesenchymal stem cells; 
IL-1β: interleukin 1 beta; IL-6: interleukin 6; LY: Lucifer 
yellow; MMP-3: matrix metalloproteinase 3; NF-κB: 
nuclear factor kappa-light-chain-enhancer of activated B 
cells; OA: osteoarthritis; OACs: osteoarthritic 
chondrocytes; OE: olive extract; OM: osteogenic 
medium; Oleu: Oleuropein; OSTCN: osteocalcin; p16: 
cyclin-dependent kinase inhibitor 2A; p53: cellular 
tumour antigen p53; PPARγ: peroxisome proliferator-
activated receptor gamma; RT-qPCR: real-time 
quantitative polymerase chain reaction; SA-βGal: 
senescence-associated β-galactosidase activity; SASP: 
senescence-associated secretory phenotype; SC: synovial 
cells; TNFα: tumour necrosis factor alpha; Twist-1: twist-
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Supplementary Figure 1. Cell viability measured by MTT assay of (A) hMSCs from both bone marrow or subcutaneous inguinal fat (n=5 
independent experiments, P=0.1065) and (B) chondrocytes (n=6 independent experiments, P=0.7871) exposed to different concentrations of 





Supplementary Figure 2. (A) Adipogenic differentiation of hMSCs exposed to different concentrations of oleuropein (Oleu) or OE. Cells 
were stained with oil red O for lipid evaluation. The graph represents the ratio of cells with lipid deposits to the total number of cells and was 
normalized to hMSCs cultured in adipogenic medium (AM) (n=3-9 independent experiments, P<0.0001). (B) Osteogenic differentiation of 
hMSCs treated with oleuropein or OE for 21 days. Alizarin red staining was performed to evaluate calcium deposits. Quantification was 
normalized to hMSCs cultured in osteogenic medium (OM) (n=4-6 independent experiments, P=0.0166). (C) Chondrogenic differentiation of 
hMSCs for 30 days exposed to different concentrations of oleuropein or OE. Images represent Col2A1 immunohistochemistry (n=4-7 
independent experiments, P=0.0609). (D) Images showing the phenotypes of hMSCs differentiated for 14 days with or without oleuropein. 
AM (adipogenic differentiation), OM (osteogenesis) and CM (chondrogenesis). Data is expressed as mean±SD, one-way ANOVA, *P<0.05, 
**P<0.01 and ***P<0.0001. 
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Supplementary Figure 3. (A) Cx43 levels analyzed by RT-qPCR of hMSCs differentiated with adipogenic (AM), osteogenic (OM) or 
chondrogenic (CM) medium for 7 and 14 days (n=2-3 independent experiments; data were normalized to HPRT-1 levels and are shown as 
mean±SD). (B) Comparative Cx43 protein levels of hMSCs cultured in chondrogenic (CM), adipogenic (AM) and osteogenic medium (OM) for 7 





Supplementary Figure 4. (A) Western blot showing increased Cx43 protein expression in hMSCs obtained from bone marrow and 
subcutaneous inguinal fat and treated for 2 h with oleuropein or olive-extract (OE) containing 41.5% Oleu as well as other polyphenolic 
compounds. α-tubulin was used as a loading control (n=5 independent experiments; one-way ANOVA, P=0.2723). RT-qPCR showing increased 
Cx43 mRNA in hMSCs treated with Oleu in basal/growth medium (α-MEM with 10% FBS) (n=9 independent experiments; data were 
normalized to HPRT-1 levels; one-way ANOVA, P=0.1041). (B) Immunofluorescence analysis showing increased Cx43 at the membrane (GJ 
plaques, white arrows) in hMSCs treated with oleuropein or OE for 2 h. Cell nuclei were stained with DAPI. Original magnifications ×40 and 
×100. Images represent two independent experiments. (C) SL/DT assay examining GJ activity in hMSCs treated with 10 µM Oleu or 10 µM OE. 
Red lines represent the cut edge where cells took up the LY immediately after scraping. The graph represents the ratio of stained cells to the 
number of cells at the scrape edge (n=10 independent experiments; Student’s t test, P=0.0087). Data is expressed as mean±SD, *P<0.05, 
**P<0.01 and ***P<0.0001. 
  
 





Supplementary Figure 5. Calcium deposits in osteogenic medium-differentiated OACs evaluated by alizarin red staining. 
OACs were cultured in osteogenic medium (OM) supplemented with 10 µM oleuropein (Oleu) or OE for 21 days. Quantification was 
performed by counting red pixels and normalization to hMSCs differentiated in osteogenic medium without treatment. n=3 technical 





Supplementary Figure 6. (A) Cell proliferation was evaluated in the T/C-28a2 chondrocyte cell line by Ki-67 immunofluorescence after 
oligomycin or Palbociclib treatment (n=3 independent experiments; mean±SD; one-way ANOVA with P<0.0001). (B) T/C-28a2 chondrocyte 
cell line was cultured with 50 µg/mL of bleomycin for 24 h, and then cultured in normal growth medium or in the presence of oleuropein 10 
µg/mL for another 24 h. The mean mean±SD of the number of cells from 5 different visual fields are shown. ß-galactosidase activity was 
detected by X-Gal cleavage, and cell staining (blue) was evaluated by microscopy. Quantification is shown on the right (n=5-10 technical 
replicates; mean±SD; one-way ANOVA with P<0.0001).  
  
 





Supplementary Table 1. List of antibodies used in flow cytometry assays. 
 
 
Supplementary Table 2. List of primer sequences (5'–3') used for RT-PCR analysis. 
Gene name (protein name) Forward Reverse 
ACAN (Aggrecan) CAGAACAACTCGGGGAACAT GCACAATTGGAACCCTGACT 

















OSTCN (Osteocalcin) CCATGAGAGCCCTCACACTCC GGTCAGCCAACTCGTCACAGTC 













CD105 PE 105PE-100T Immunostep 488  585/42 1:50 
CD166 APC 1399990314 Immunostep 635  661/16 1:100 
Cx43 APC FAB7737A R&D 635  661/16 1:50 
